1-3 of 3
Brian Law
Close
Sort by
Journal Articles

Bmf-500: An Orally Bioavailable Covalent Inhibitor of FLT3 with High Selectivity and Potent Antileukemic Activity in FLT3-Mutated AML

Brian Law, Tripta Rughwani, Tenley C. Archer, Lekha Kumar, Daniel Lu, Priyanka Somanath, Yan Ma, Xiaodong Wang, David Sperandio, Steve Morris, Thorsten Kirschberg, Mini Balakrishnan, Thomas Butler
Journal: Blood
Blood (2022) 140 (Supplement 1): 6191–6192.
https://doi.org/10.1182/blood-2022-170445
Published: 2022
Journal Articles

Novel Irreversible Menin Inhibitor, BMF-219, Shows Potent Single Agent Activity in Clinically Relevant DLBCL Cells

Priyanka Somanath, Daniel Lu, Brian Law, Tenley C. Archer, Alexandru Cacovean, James T. Palmer, Taisei Kinoshita, Thomas Butler
Journal: Blood
Blood (2021) 138 (Supplement 1): 4318.
https://doi.org/10.1182/blood-2021-148045
Published: 2021
Journal Articles

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Elena Bibikova, Brian Law, Tracy Clevenger, PhD, Jean Cheung, MS, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, PhD, Graham Brock, PhD, Veerendra Munugalavadla, PhD, Melanie M. Frigault, PhD, John C. Byrd, MD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD, Todd Covey
Journal: Blood
Blood (2019) 134 (Supplement_1): 2571.
https://doi.org/10.1182/blood-2019-128872
Published: 2019